{"id":226920,"date":"2025-12-11T10:07:13","date_gmt":"2025-12-11T16:07:13","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/12\/prognostic-tool-could-help-clinicians-identify-high-risk-cancer-patients"},"modified":"2025-12-11T10:07:13","modified_gmt":"2025-12-11T16:07:13","slug":"prognostic-tool-could-help-clinicians-identify-high-risk-cancer-patients","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/12\/prognostic-tool-could-help-clinicians-identify-high-risk-cancer-patients","title":{"rendered":"Prognostic tool could help clinicians identify high-risk cancer patients"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/prognostic-tool-could-help-clinicians-identify-high-risk-cancer-patients2.jpg\"><\/a><\/p>\n<p>The MIT researchers have spent the past few years developing the Synthetic Survival Control causal inference framework, which enables them to answer complex \u201cwhen-if\u201d questions when using available data is statistically challenging. Their approach estimates when a target event happens if a certain intervention is used.<\/p>\n<p>In this paper, the researchers investigated an aggressive cancer called nodal mature T-cell lymphoma, and whether a certain prognostic marker led to worse outcomes. The marker, TTR12, signifies that a patient relapsed within 12 months of initial therapy.<\/p>\n<p>They applied their framework to estimate when a patient will die if they have TTR12, and how their survival trajectory would be different if they do not have this prognostic marker.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The MIT researchers have spent the past few years developing the Synthetic Survival Control causal inference framework, which enables them to answer complex \u201cwhen-if\u201d questions when using available data is statistically challenging. Their approach estimates when a target event happens if a certain intervention is used. In this paper, the researchers investigated an aggressive cancer [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-226920","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/226920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=226920"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/226920\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=226920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=226920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=226920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}